Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945386 | 1.00 | LMNA (0.45) | LMNAAGTR1CYP1A2POLBHTT | |
| SCHEMBL16920272 | 0.89 | ALDH1A1 (0.44) | LMNAAGTR1CYP1A2NPSR1L3MBTL1 | |
| SCHEMBL16920273 | 0.89 | ALDH1A1 (0.44) | LMNAAGTR1CYP1A2NPSR1L3MBTL1 | |
| SCHEMBL19361589 | 0.83 | CYP1A2 (0.46) | LMNAAGTR1CYP1A2POLBHTT | |
| SCHEMBL19361578 | 0.83 | LMNA (0.42) | LMNAAGTR1CYP1A2POLBHTT | |
| SCHEMBL19361586 | 0.82 | KDM4E (0.38) | TSHRMAPTMAPK1 | |
| SCHEMBL20220648 | 0.81 | LMNA (0.49) | LMNAAGTR1CYP1A2POLBHTT | |
| SCHEMBL18820706 | 0.80 | AGTR1 (0.41) | LMNAAGTR1CYP1A2POLBHTT | |
| SCHEMBL14945341 | 0.79 | AGTR1 (0.45) | LMNAAGTR1CYP1A2POLBHTT | |
| SCHEMBL14945342 | 0.79 | AGTR1 (0.45) | LMNAAGTR1CYP1A2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3329919-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190330224-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-10-31 | — | — | US | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| US-10179793-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-01-15 | — | — | US | disclosed |
| EP-3329919-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-10179793-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-20190330224-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | LMNA 3238/4885AGTR1 1646/4885CYP1A2 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.